239 related articles for article (PubMed ID: 33247158)
1. Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma.
Federico C; Alhallak K; Sun J; Duncan K; Azab F; Sudlow GP; de la Puente P; Muz B; Kapoor V; Zhang L; Yuan F; Markovic M; Kotsybar J; Wasden K; Guenthner N; Gurley S; King J; Kohnen D; Salama NN; Thotala D; Hallahan DE; Vij R; DiPersio JF; Achilefu S; Azab AK
Nat Commun; 2020 Nov; 11(1):6037. PubMed ID: 33247158
[TBL] [Abstract][Full Text] [Related]
2. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment.
Azab AK; Quang P; Azab F; Pitsillides C; Thompson B; Chonghaile T; Patton JT; Maiso P; Monrose V; Sacco A; Ngo HT; Flores LM; Lin CP; Magnani JL; Kung AL; Letai A; Carrasco R; Roccaro AM; Ghobrial IM
Blood; 2012 Feb; 119(6):1468-78. PubMed ID: 22096244
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
[TBL] [Abstract][Full Text] [Related]
4. Bone-Targeted Bortezomib Inhibits Bortezomib-Resistant Multiple Myeloma in Mice by Providing Higher Levels of Bortezomib in Bone.
Tao J; Srinivasan V; Yi X; Zhao Y; Zhang H; Lin X; Zhou X; Boyce BF; Villalta PW; Ebetino FH; Ho KK; Boeckman RK; Xing L
J Bone Miner Res; 2022 Apr; 37(4):629-642. PubMed ID: 34970782
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
[TBL] [Abstract][Full Text] [Related]
6. BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma.
Dutta D; Liu J; Wen K; Kurata K; Fulciniti M; Gulla A; Hideshima T; Anderson KC
Blood Cancer J; 2023 Dec; 13(1):184. PubMed ID: 38072962
[TBL] [Abstract][Full Text] [Related]
7. Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.
de la Puente P; Luderer MJ; Federico C; Jin A; Gilson RC; Egbulefu C; Alhallak K; Shah S; Muz B; Sun J; King J; Kohnen D; Salama NN; Achilefu S; Vij R; Azab AK
J Control Release; 2018 Jan; 270():158-176. PubMed ID: 29196043
[TBL] [Abstract][Full Text] [Related]
8. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
Yasui H; Hideshima T; Ikeda H; Jin J; Ocio EM; Kiziltepe T; Okawa Y; Vallet S; Podar K; Ishitsuka K; Richardson PG; Pargellis C; Moss N; Raje N; Anderson KC
Br J Haematol; 2007 Feb; 136(3):414-23. PubMed ID: 17173546
[TBL] [Abstract][Full Text] [Related]
9. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma.
Zheng Y; Yang J; Qian J; Qiu P; Hanabuchi S; Lu Y; Wang Z; Liu Z; Li H; He J; Lin P; Weber D; Davis RE; Kwak L; Cai Z; Yi Q
Leukemia; 2013 Mar; 27(3):702-10. PubMed ID: 22996336
[TBL] [Abstract][Full Text] [Related]
10. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
[TBL] [Abstract][Full Text] [Related]
11. ROS Overproduction Sensitises Myeloma Cells to Bortezomib-Induced Apoptosis and Alleviates Tumour Microenvironment-Mediated Cell Resistance.
Caillot M; Zylbersztejn F; Maitre E; Bourgeais J; Hérault O; Sola B
Cells; 2020 Oct; 9(11):. PubMed ID: 33114738
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
13. Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib.
Tang JX; Chen Q; Li Q; He YH; Xiao D
Cell Biol Int; 2021 May; 45(5):965-975. PubMed ID: 33372728
[TBL] [Abstract][Full Text] [Related]
14. Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts.
Chen P; Yuan Q; Yang H; Wen X; You P; Hou D; Xie J; Cheng Y; Huang H
Leuk Res; 2017 Jun; 57():119-126. PubMed ID: 28463768
[TBL] [Abstract][Full Text] [Related]
15. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
Zuccari G; Milelli A; Pastorino F; Loi M; Petretto A; Parise A; Marchetti C; Minarini A; Cilli M; Emionite L; Di Paolo D; Brignole C; Piaggio F; Perri P; Tumiatti V; Pistoia V; Pagnan G; Ponzoni M
J Control Release; 2015 Aug; 211():44-52. PubMed ID: 26031842
[TBL] [Abstract][Full Text] [Related]
16. A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe.
Hu L; Li B; Chen G; Song D; Xu Z; Gao L; Xi M; Zhou J; Li L; Zhang H; Feng Q; Wang Y; Lu K; Lu Y; Bu W; Wang H; Wu X; Zhu W; Shi J
J Exp Clin Cancer Res; 2020 Jun; 39(1):105. PubMed ID: 32517809
[TBL] [Abstract][Full Text] [Related]
17. Caffeine inhibits migration in glioma cells through the ROCK-FAK pathway.
Chen Y; Chou WC; Ding YM; Wu YC
Cell Physiol Biochem; 2014; 33(6):1888-98. PubMed ID: 25011614
[TBL] [Abstract][Full Text] [Related]
18. Engineered nanomedicine for myeloma and bone microenvironment targeting.
Swami A; Reagan MR; Basto P; Mishima Y; Kamaly N; Glavey S; Zhang S; Moschetta M; Seevaratnam D; Zhang Y; Liu J; Memarzadeh M; Wu J; Manier S; Shi J; Bertrand N; Lu ZN; Nagano K; Baron R; Sacco A; Roccaro AM; Farokhzad OC; Ghobrial IM
Proc Natl Acad Sci U S A; 2014 Jul; 111(28):10287-92. PubMed ID: 24982170
[TBL] [Abstract][Full Text] [Related]
19. Rho Kinase Inhibition by AT13148 Blocks Pancreatic Ductal Adenocarcinoma Invasion and Tumor Growth.
Rath N; Munro J; Cutiongco MF; Jagiełło A; Gadegaard N; McGarry L; Unbekandt M; Michalopoulou E; Kamphorst JJ; Sumpton D; Mackay G; Vennin C; Pajic M; Timpson P; Olson MF
Cancer Res; 2018 Jun; 78(12):3321-3336. PubMed ID: 29669760
[TBL] [Abstract][Full Text] [Related]
20. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
Zaman S; Shentu S; Yang J; He J; Orlowski RZ; Stellrecht CM; Gandhi V
Neoplasia; 2015 Mar; 17(3):289-300. PubMed ID: 25810013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
